Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have lost more than half their value over the past 12 months.

Wall Street is heading toward the finish of a strong week on Friday as U.S. stocks drift close to the all-time high they set just a few months earlier, though it may feel like an economic era ago.

In a volatile and uncertain time on Wall Street, it may seem like folly to make investment decisions based on where your portfolio will be years down the road. But many books have been written ...

Key Takeaways Novo Nordisk is teaming up with U.S. biotech Septerna to create a new obesity pillSepterna could receive up to ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk CEO Lars Fruergaard Jorgensen steps down amidst concerns over losing their competitive edge in the obesity drug market. Analysts react, citing the need for a CEO familiar with the U.S.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Novo Nordisk's CEO Lars Fruergaard Jorgensen was ousted as the company struggles to maintain its dominance in the highly ...